This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Endocrine Diseases  • Otolaryngology/ Head & Neck Surgery  • Alert me on articles by topic

Adrienne M. Feasel, MD; Michele L. Donato, MD; Madeleine Duvic, MD

Arch Dermatol. 2001;137:1071-1072.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Scleromyxedema is characterized by dermal fibroblast proliferation and mucin deposition, associated with plasma cell dyscrasia. Therapy for systemic progression is often not effective, and the disease is potentially fatal.¹ We describe a man with rapidly progressive scleromyxedema in whom multiple treatments had failed before complete remission was achieved with treatment with high-dose pulse dexamethasone, high-dose melphalan, and autologous stem cell transplantation.

REPORT OF A CASE

A 46-year-old white man was referred to the M. D. Anderson Cancer Center, Houston, Tex, to undergo photopheresis for scleromyxedema. Six years earlier, pruritic papules appeared on the dorsal part of his hands but resolved with oral and topical corticosteroid therapy. Three years later, the lesions returned as waxy plaques, thickened skin, and orbital swelling. A skin biopsy specimen showed dermal mucinosis and fibrosis, consistent with scleromyxedema. IgG light chain plasma cell dyscrasia was noted on serum electrophoresis. . . . [Full Text of this Article]

COMMENT

From the Departments of Dermatology (Drs Feasel and Duvic) and Bone Marrow Transplantation (Dr Donato), The University of Texas, M. D. Anderson Cancer Center, Houston.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study.
Illa et al.
Blood 2006;108:773-774.
FULL TEXT  

Transplantation for cutaneous disease
Gertz
Blood 2006;107:415-415.
FULL TEXT  

Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation
Donato et al.
Blood 2006;107:463-466.
ABSTRACT | FULL TEXT  

Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation
Lacy et al.
Arch Dermatol 2005;141:1277-1282.
ABSTRACT | FULL TEXT